Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

MLA

Boss, D. S., et al. “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral Cyclin-Dependent Kinase Inhibitor AZD5438 When Administered at Intermittent and Continuous Dosing Schedules in Patients with Advanced Solid Tumours.” Annals of Oncology, vol. 21, no. 4, Apr. 2010, pp. 884–94. EBSCOhost, https://doi.org/10.1093/annonc/mdp377.

APA

Boss, D. S., Schwartz, G. K., Middleton, M. R., Amakye, D. D., Swaisland, H., Midgley, R. S., Ranson, M., Danson, S., Calvert, H., Plummer, R., Morris, C., Carvajal, R. D., Chirieac, L. R., Schellens, J. H. M., & Shapiro, G. I. (2010). Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Annals of Oncology, 21(4), 884–894. https://doi.org/10.1093/annonc/mdp377

Chicago

Boss, D. S., G. K. Schwartz, M. R. Middleton, D. D. Amakye, H. Swaisland, R. S. Midgley, M. Ranson, et al. 2010. “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral Cyclin-Dependent Kinase Inhibitor AZD5438 When Administered at Intermittent and Continuous Dosing Schedules in Patients with Advanced Solid Tumours.” Annals of Oncology 21 (4): 884–94. doi:10.1093/annonc/mdp377.